Nitrile-containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2010 Sep 1

PMID 20804202

Citations 212

Authors

Fraser F Fleming

Lihua Yao

P C Ravikumar

Lee Funk

Brian C Shook

Affiliations

Soon will be listed here.

Citing Articles

Mechanistic insights into novel cyano-pyrimidine pendant chalcone derivatives as LSD1 inhibitors by docking, ADMET, MM/GBSA, and molecular dynamics simulation.

Gupta A, Parveen D, Azam F, Shaquiquzzaman M, Akhter M, Jaremko M Biochem Biophys Rep. 2025; 41:101937.

PMID: 40028038 PMC: 11871483. DOI: 10.1016/j.bbrep.2025.101937.

l-Proline catalysed synthesis and studies of novel α-cyano bis(indolyl)chalcones as potential anti-cancer agents.

Malik M, Roy N, Sakkarai Mohamed A, Lotana H, Shah K, Kumar D RSC Adv. 2025; 15(6):4593-4606.

PMID: 39931398 PMC: 11809490. DOI: 10.1039/d4ra06796g.

Dibenzothiophenium Salts: Practical Alternatives to Hypervalent I(III)-Based Reagents.

Alcarazo M Acc Chem Res. 2025; 58(4):635-646.

PMID: 39895033 PMC: 11840934. DOI: 10.1021/acs.accounts.4c00804.

BrCFCN for photocatalytic cyanodifluoromethylation.

Yang X, Lin J, Xiao J Nat Commun. 2025; 16(1):445.

PMID: 39774954 PMC: 11707358. DOI: 10.1038/s41467-024-55797-4.

Hydrogen Bond Blueshifts in Nitrile Vibrational Spectra Are Dictated by Hydrogen Bond Geometry and Dynamics.

Kirsh J, Kozuch J JACS Au. 2024; 4(12):4844-4855.

PMID: 39735926 PMC: 11672138. DOI: 10.1021/jacsau.4c00811.

References

Bose P, Ozer H . Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs. 2009; 18(11):1735-51. DOI: 10.1517/13543780903305428. View

Oballa R, Truchon J, Bayly C, Chauret N, Day S, Crane S . A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg Med Chem Lett. 2006; 17(4):998-1002. DOI: 10.1016/j.bmcl.2006.11.044. View

Caponigro F, Casale M, Bryce J . Farnesyl transferase inhibitors in clinical development. Expert Opin Investig Drugs. 2003; 12(6):943-54. DOI: 10.1517/13543784.12.6.943. View

Okamoto K, Matsumoto K, Hille R, Eger B, Pai E, Nishino T . The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A. 2004; 101(21):7931-6. PMC: 419534. DOI: 10.1073/pnas.0400973101. View

Horstkotter C, Schepmann D, Blaschke G . Separation and identification of zaleplon metabolites in human urine using capillary electrophoresis with laser-induced fluorescence detection and liquid chromatography-mass spectrometry. J Chromatogr A. 2003; 1014(1-2):71-81. DOI: 10.1016/s0021-9673(03)00564-8. View

Mowbray C, Burt C, Corbau R, Gayton S, Hawes M, Perros M . Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett. 2009; 19(20):5857-60. DOI: 10.1016/j.bmcl.2009.08.080. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Boyd M, Crane S, Robichaud J, Scheigetz J, Black W, Chauret N . Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors. Bioorg Med Chem Lett. 2009; 19(3):675-9. DOI: 10.1016/j.bmcl.2008.12.053. View

Keseru G, Makara G . The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 2009; 8(3):203-12. DOI: 10.1038/nrd2796. View

10.

Sanchez C . The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol. 2006; 99(2):91-5. DOI: 10.1111/j.1742-7843.2006.pto_295.x. View

11.

DeLong A, Oldham S, DeSante K, Nell G, Henry D . Disposition of [14C]pinacidil in humans. J Pharm Sci. 1988; 77(2):153-6. DOI: 10.1002/jps.2600770212. View

12.

Sato T, Ashizawa N, Matsumoto K, Iwanaga T, Nakamura H, Inoue T . Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009; 19(21):6225-9. DOI: 10.1016/j.bmcl.2009.08.091. View

13.

Dhillon S, Weber J . Saxagliptin. Drugs. 2009; 69(15):2103-14. DOI: 10.2165/11201170-000000000-00000. View

14.

Ward Y, Thomson D, Frye L, Cywin C, Morwick T, Emmanuel M . Design and synthesis of dipeptide nitriles as reversible and potent Cathepsin S inhibitors. J Med Chem. 2002; 45(25):5471-82. DOI: 10.1021/jm020209i. View

15.

Erlichman C, Hidalgo M, Boni J, Martins P, Quinn S, Zacharchuk C . Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2006; 24(15):2252-60. DOI: 10.1200/JCO.2005.01.8960. View

16.

Pascual E, Sivera F, Yasothan U, Kirkpatrick P . Febuxostat. Nat Rev Drug Discov. 2009; 8(3):191-2. DOI: 10.1038/nrd2831. View

17.

Wellington K, Keam S . Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer. Drugs Aging. 2007; 24(2):169-71. DOI: 10.2165/00002512-200724020-00008. View

18.

Roumen L, Peeters J, Emmen J, Beugels I, Custers E, De Gooyer M . Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010; 53(4):1712-25. DOI: 10.1021/jm901356d. View

19.

Jackson L, STAFFORD J . The evaluation and application of a radioimmunoassay for the measurement of diphenoxylic acid, the major metabolite of diphenoxylate hydrochloride (Lomotil), in human plasma. J Pharmacol Methods. 1987; 18(3):189-97. DOI: 10.1016/0160-5402(87)90069-6. View

20.

Tsou H, Overbeek-Klumpers E, Hallett W, Reich M, Floyd M, Johnson B . Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem. 2005; 48(4):1107-31. DOI: 10.1021/jm040159c. View